THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [12.18]-C166 ID: TIP-MED-000436

Risedronate Sodium

Active Ingredient / Scientific Identity: Risedronate Sodium • Class: Nitrogen-Containing Oral Bisphosphonate (Osteoclast Farnesyl Pyrophosphate Synthase Inhibitor)

⚖️ Compare Profile
Generic / Entity NameRisedronate Sodium ([12.18]-C166)
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassNitrogen-Containing Oral Bisphosphonate (Osteoclast Farnesyl Pyrophosphate Synthase Inhibi
Available Dosage FormsTablet: 10 mg (daily), 35 mg (weekly), 70 mg (weekly; alone or with Cholecalciferol 2800 IU / 5600 IU).
Regulatory ClassificationSchedule H Prescription Drug (To be sold by retail on the prescription of a Registere
Key Warning & Review DateRenal: eGFR <35 mL/min: CONTRAINDICATED (renal elimination; risk of adynamic bone disease and nephrotoxicity). • Hepatic: No
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug (To be sold by retail o✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Risedronate Sodium (TIP-MED-000436, Reference Code [12.18]-C166) is classified under Osteoporosis & Bone Metabolism Medicines (Ch 12) as a Nitrogen-Containing Oral Bisphosphonate (Osteoclast Farnesyl Pyrophosphate Synthase Inhibitor). Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Co-indexed constituent under primary monograph [12.18] (Alendronate Sodium & Risedronate (Weekly Oral Bisphosphonates)). Representative Indian Market Examples (Edition 2.7 Ch 12 [12.18], p. 163): Osteofos, Stoplos, Restofos — Strengths & Dosage Forms: Tablet: 10 mg (daily), 35 mg (weekly), 70 mg (weekly; alone or with Cholecalciferol 2800 IU / 5600 IU).
Co-indexed constituent under primary monograph [12.18] (Alendronate Sodium & Risedronate (Weekly Oral Bisphosphonates)). Representative Indian Market Examples (Edition 2.7 Ch 12 [12.18], p. 163): Osteofos, Stoplos, Restofos — Strengths & Dosage Forms: Tablet: 10 mg (daily), 35 mg (weekly), 70 mg (weekly; alone or with Cholecalciferol 2800 IU / 5600 IU).
Dosage Forms & Available Strengths:
Tablet: 10 mg (daily), 35 mg (weekly), 70 mg (weekly; alone or with Cholecalciferol 2800 IU / 5600 IU).
Routes: Oral / Parenteral / Topical per formulation

3. Mechanism of Action & Pharmacodynamics

Binds hydroxyapatite crystals in bone and is internalised by resorbing osteoclasts -> inhibits mevalonate pathway enzyme farnesyl pyrophosphate synthase -> induces osteoclast apoptosis and suppresses bone turnover.

4. Therapeutic Indications & Evidence-Supported Uses

  • Postmenopausal osteoporosis
  • male osteoporosis
  • glucocorticoid-induced osteoporosis

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Adult: Treatment of Osteoporosis: 70 mg PO ONCE WEEKLY on the same day each week (or 10 mg once daily). Prevention: 35 mg PO once weekly. • Paediatric: Specialist osteogenesis imperfecta protocols only.

Administration & Meal Timing: See Administration & Counselling below. | Standard clinical schedule per indication.

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Follows class pharmacokinetic profile detailed in parent monograph [12.18].
Metabolism & Biotransformation:
Renal: eGFR <35 mL/min: CONTRAINDICATED (renal elimination; risk of adynamic bone disease and nephrotoxicity). • Hepatic: No adjustment required (not metabolised by liver).
Elimination & Renal Adjustment:
Renal: eGFR <35 mL/min: CONTRAINDICATED (renal elimination; risk of adynamic bone disease and nephrotoxicity). • Hepatic: No adjustment required (not metabolised by liver).
Hepatic Impairment Considerations:
Renal: eGFR <35 mL/min: CONTRAINDICATED (renal elimination; risk of adynamic bone disease and nephrotoxicity). • Hepatic: No adjustment required (not metabolised by liver).

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Contraindications: Oesophageal stricture, achalasia, or delayed oesophageal emptying; inability to stand or sit upright for at least 30 minutes; hypocalcaemia (must correct vitamin D and calcium deficiency first); eGFR <35 mL/min. • Precautions: Extremely poor oral bioavailability (<1%) that is completely abolished (reduced by 60-90%) by food, coffee, tea, juice, mineral water, calcium, iron, or levothyroxine; causes corrosive pill oesophagitis if lodged in oesophagus; rare osteonecrosis of the jaw (ONJ) after invasive dental extractions and atypical subtrochanteric femoral fractures after >5 years.

Key Clinical Precautions: Renal: eGFR <35 mL/min: CONTRAINDICATED (renal elimination; risk of adynamic bone disease and nephrotoxicity). • Hepatic: No adjustment required (not metabolised by liver).

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Dyspepsia, abdominal pain, musculoskeletal pain, acid regurgitation.
  • Erosive oesophagitis, oesophageal ulceration/stricture, osteonecrosis of the jaw (ONJ), atypical femur fracture, hypocalcaemia.
Serious / Dose-Limiting Adverse Effects:

    9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

    • Calcium, Iron, Magnesium, Antacids, Sucralfate, Levothyroxine, Milk/Tea/Coffee -> chelate alendronate and abolish absorption (wait >=30-60 minutes before taking ANY food, beverage, or other morning medication including Levothyroxine if taken on the same day); NSAIDs/Aspirin -> additive upper GI ulceration

    10. Clinical Monitoring, Patient Counselling & Storage

    Clinical & Laboratory Monitoring: Monitor clinical parameters per parent monograph [12.18].

    Pharmacist Patient Counselling Points:

    • Patient Counselling Checklist: MANDATORY 4-RULE ADMINISTRATION: (1) Take ONCE A WEEK first thing in the morning on an empty stomach, (2) Swallow whole with a full glass (200 mL) of plain tap water ONLY (not mineral water, tea, coffee, or milk), (3) Remain fully upright (sitting or standing—do NOT lie down) for at least 30 minutes, (4) Wait at least 30 minutes before eating breakfast or taking Calcium/Iron/Thyroxine tablets.
    • Meal & Clock Timing Instruction: See Administration & Counselling below. (Standard clinical schedule per indication.)
    • Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
    • Geriatric Dispensing Pearl: Schedule: Schedule H | NLEM 2022: Yes | Compendia: IP 2026 / NFI 7th Ed 2026 / NLEM 2022 / CDSCO Schedule H / BNF 90th Ed

    Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Tablet: 10 mg (daily), 35 mg (weekly), 70 mg (weekly; alone or with Cholecalciferol 2800 IU / 5600 IU).

    11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

    THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
    svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

    12. Authoritative References, Regulatory Sources & Editorial Disclaimer

    Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO

    Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

    Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

    Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.